These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 1532818)
21. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition. Stevens EJ; Jacknin L; Robbins PF; Kawakami Y; el Gamil M; Rosenberg SA; Yannelli JR J Immunol; 1995 Jan; 154(2):762-71. PubMed ID: 7814882 [TBL] [Abstract][Full Text] [Related]
22. Activation of human tumor-infiltrating lymphocytes by monoclonal antibodies directed to the CD3 complex. Schoof DD; Selleck CM; Massaro AF; Jung SE; Eberlein TJ Cancer Res; 1990 Feb; 50(4):1138-43. PubMed ID: 2137027 [TBL] [Abstract][Full Text] [Related]
23. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210 [TBL] [Abstract][Full Text] [Related]
24. Immune stimulatory and anti-tumor properties of anti-CD3 and BAT monoclonal antibodies: a comparative study. Hardy B; Kovjazin R; Raiter A; Ganor N; Novogrodsky A Hum Antibodies; 1997; 8(2):95-8. PubMed ID: 9289394 [TBL] [Abstract][Full Text] [Related]
25. In vivo antitumor activity of anti-CD3-induced activated killer cells. Yun YS; Hargrove ME; Ting CC Cancer Res; 1989 Sep; 49(17):4770-4. PubMed ID: 2527087 [TBL] [Abstract][Full Text] [Related]
26. Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. Kawakami Y; Zakut R; Topalian SL; Stötter H; Rosenberg SA J Immunol; 1992 Jan; 148(2):638-43. PubMed ID: 1729379 [TBL] [Abstract][Full Text] [Related]
27. Efficacy of tumor-infiltrating lymphocytes in the treatment of hepatic metastases arising from transgenic intraocular tumors in mice. Ma D; Niederkorn JY Invest Ophthalmol Vis Sci; 1995 May; 36(6):1067-75. PubMed ID: 7730016 [TBL] [Abstract][Full Text] [Related]
29. Targeting human cytotoxic T lymphocytes to kill heterologous epidermal growth factor receptor-bearing tumor cells. Tumor-infiltrating lymphocyte/hormone receptor/recombinant antibody. Gillies SD; Wesolowski JS; Lo KM J Immunol; 1991 Feb; 146(3):1067-71. PubMed ID: 1824849 [TBL] [Abstract][Full Text] [Related]
30. Targeted cellular immunotherapy with bifunctional antibodies. Nelson H Cancer Cells; 1991 May; 3(5):163-72. PubMed ID: 1832553 [TBL] [Abstract][Full Text] [Related]
31. Augmentation of interleukin-2-induced activation of human melanoma tumor-infiltrating lymphocytes by heteroconjugate antibody. Mansfield PF; Rosenblum MG; Murray JL; Itoh K Cancer Immunol Immunother; 1991; 33(4):247-54. PubMed ID: 1829394 [TBL] [Abstract][Full Text] [Related]
32. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3). Demanet C; Brissinck J; Van Mechelen M; Leo O; Thielemans K J Immunol; 1991 Aug; 147(3):1091-7. PubMed ID: 1830596 [TBL] [Abstract][Full Text] [Related]
33. Antitumor x anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with staphylococcal enterotoxin B to neutralize pulmonary metastases. Penna C; Dean PA; Nelson H Cancer Res; 1994 May; 54(10):2738-43. PubMed ID: 8168104 [TBL] [Abstract][Full Text] [Related]
34. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity. Anderson PM; Blazar BR; Bach FH; Ochoa AC J Immunol; 1989 Feb; 142(4):1383-94. PubMed ID: 2521662 [TBL] [Abstract][Full Text] [Related]
35. Human tumor-infiltrating CD4+ T cells react to B cell lines expressing heat shock protein 70. Yoshino I; Goedegebuure PS; Peoples GE; Lee KY; Eberlein TJ J Immunol; 1994 Nov; 153(9):4149-58. PubMed ID: 7930618 [TBL] [Abstract][Full Text] [Related]
36. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes. Wang YL; Si LS; Kanbour A; Herberman RB; Whiteside TL Cancer Res; 1989 Nov; 49(21):5979-85. PubMed ID: 2507139 [TBL] [Abstract][Full Text] [Related]
37. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. Weiner GJ; Hillstrom JR J Immunol; 1991 Dec; 147(11):4035-44. PubMed ID: 1834746 [TBL] [Abstract][Full Text] [Related]
38. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies. Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962 [TBL] [Abstract][Full Text] [Related]
39. Down-regulation of tumoricidal NK and NK T cell activities by MHC Kb molecules expressed on Th2-type gammadelta T and alphabeta T cells coinfiltrating in early B16 melanoma lesions. Seo N; Tokura Y; Furukawa F; Takigawa M J Immunol; 1998 Oct; 161(8):4138-45. PubMed ID: 9780186 [TBL] [Abstract][Full Text] [Related]
40. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes. Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]